Biochemical and crystallographic studies of L,D-transpeptidase 2 from Mycobacterium tuberculosis with its natural monomer substrate.

Biochemical and crystallographic studies of L,D-transpeptidase 2 from Mycobacterium tuberculosis with its natural monomer substrate.

Publication date: Sep 18, 2024

The essential L,D-transpeptidase of Mycobacterium tuberculosis (Ldt) catalyses the formation of 3 3 cross-links in cell wall peptidoglycan and is a target for development of antituberculosis therapeutics. Efforts to inhibit Ldt have been hampered by lack of knowledge of how it binds its substrate. To address this gap, we optimised the isolation of natural disaccharide tetrapeptide monomers from the Corynebacterium jeikeium bacterial cell wall through overproduction of the peptidoglycan sacculus. The tetrapeptides were used in binding / turnover assays and biophysical studies on Ldt We determined a crystal structure of wild-type Ldt reacted with its natural substrate, the tetrapeptide monomer of the peptidoglycan layer. This structure shows formation of a thioester linking the catalytic cysteine and the donor substrate, reflecting an intermediate in the transpeptidase reaction; it informs on the mode of entrance of the donor substrate into the Ldt active site. The results will be useful in design of Ldt inhibitors, including those based on substrate binding interactions, a strategy successfully employed for other nucleophilic cysteine enzymes.

Open Access PDF

Concepts Keywords
Crystallographic Bacterial Proteins
Inhibitors Bacterial Proteins
Mycobacterium Catalytic Domain
Peptidoglycan Cell Wall
Wild Corynebacterium
Crystallography, X-Ray
Models, Molecular
Mycobacterium tuberculosis
Peptidoglycan
Peptidoglycan
Peptidyl Transferases
Peptidyl Transferases
Substrate Specificity

Semantics

Type Source Name
drug DRUGBANK Telbivudine
drug DRUGBANK L-Cysteine
disease IDO site
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH bacterial infections
drug DRUGBANK Serine
drug DRUGBANK Glycine
disease IDO bacteria
drug DRUGBANK Histidine
drug DRUGBANK Alpha-Linolenic Acid
drug DRUGBANK Ebselen
drug DRUGBANK Glutamic Acid
drug DRUGBANK Amifampridine
drug DRUGBANK Trypsin
drug DRUGBANK Lysozyme
drug DRUGBANK Coenzyme M
drug DRUGBANK Amino acids
drug DRUGBANK Ampicillin
drug DRUGBANK Acridine Carboxamide
drug DRUGBANK L-Lysine
disease IDO protein
disease IDO assay
drug DRUGBANK Ammonia
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Tromethamine
disease IDO biological process
drug DRUGBANK Water
drug DRUGBANK Activated charcoal
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Enterococcus faecium
drug DRUGBANK Meropenem
drug DRUGBANK Biapenem
drug DRUGBANK Ertapenem
disease MESH COVID 19
disease IDO production
drug DRUGBANK Faropenem
drug DRUGBANK Flavin adenine dinucleotide
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
disease IDO cell
drug DRUGBANK Imidazole
drug DRUGBANK Flunarizine
drug DRUGBANK Sodium lauryl sulfate
disease IDO blood
drug DRUGBANK Acetic acid
drug DRUGBANK L-Alanine
drug DRUGBANK Dacarbazine
drug DRUGBANK Formic Acid
disease IDO nucleic acid
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Cysteamine
drug DRUGBANK Nitrogen
drug DRUGBANK Trestolone
drug DRUGBANK L-Aspartic Acid
pathway KEGG Peptidoglycan biosynthesis
disease IDO virulence
drug DRUGBANK Amoxicillin
drug DRUGBANK Vancomycin
pathway REACTOME Reproduction

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *